Doug is CEO of Kleo Pharmaceuticals. He has 20 years’ experience in drug development. He was the Senior Vice President, Head of Specialty Development and Head of Japan and China R&D at BMS until October 2016. He had leadership roles at BMS overseeing various therapeutic areas including virology, immunoscience, neurology, cardiology, metabolic diseases, genetically-defined diseases and fibrosis since joining in 2005. From 2001 to 2005, he was Vice President of Clinical Development and Medical Affairs for HIV/AIDS at GSK. He started his career at DuPont Pharmaceuticals in 1997. He is Board Certified in Internal Medicine and completed his Fellowship in Infectious Diseases in Ottawa Canada and a clinical and bench research fellowship at Massachusetts General Hospital and Harvard Medical School. Doug also serves on the Board of Directors of Celleron Therapeutics.